Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma
Completed · Phase 2
Conditions studied: Advanced Melanoma
In brief
ATLAS-IT-05 is an open-label, single-arm study in patients with advanced melanoma accessible for injections (cutaneous, subcutaneous, lymph node, or intramuscular tumors) and who have either exhausted treatment options or are not eligible for, suitable for, or willing to undergo such treatments.
Key facts
- Study ID
- NCT04796194
- Run by
- Lytix Biopharma AS
- People needed
- 23
- Starts
- 2021-06-01
- Expected to finish
- 2025-07-01
- Last updated by the study team
- 2025-11-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Icahn School of Medicine at Mount Sinai — New York, New York, United States
- Levine Cancer Institute - Atrium Health — Charlotte, North Carolina, United States
- University of Pittsburgh Medical Center (UPMC) Hilman Cancer Center — Pittsburgh, Pennsylvania, United States
- MD Anderson Cancer Centre — Houston, Texas, United States
- Centre Hospitalier Regional Universitaire De Lille — Lille, France
- Gustave Roussy Cancer Campus — Paris, France
- Hospital Lyon Sud — Pierre-Bénite, France
- Akershus University Hospital — Lørenskog, Norway
- Oslo University Hospital--Radiumhospitalet — Oslo, Norway
- Clínica Universidad de Navarra — Pamplona, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.